Sanofi Consumer Healthcare India Ltd

Sanofi Consumer Healthcare India Limited Trading Window Closed from 1st October 2026 till 48 hours after the announcement of Unaudited Standalone Financial Results for the quarter and nine months ended 30th September 2026

Financial results approved

• Board approved unaudited results for quarter and half-year ended 30 June 2026.
• Q2 2026 revenue ₹2,357 million; PBT ₹919 million; PAT ₹688 million.
• HY 2026 revenue ₹4,649 million; PBT ₹1,826 million; PAT ₹1,366 million.
• Basic EPS: Q2 ₹29.87; HY ₹59.31.
• Dividend not declared for HY ended 30 June 2026.

Regulatory and audit notes

• PwC performed limited review; no material misstatement observed.
• 2026 results prepared under Ind AS; review report unmodified.
• New Labour Codes: ₹24 million past service cost recognised; gratuity liability up.
• Recall and relaunch of Combiflam, Allegra, Depura reflected; comparability affected.
• Single business segment; no subsidiaries, associates, or joint ventures.

Dematerialisation status

• Dematerialisation requests received during the period were processed and confirmed to the depositories.
• Dematerialised securities have been listed on the exchanges where earlier issues are listed.
• Physical certificates received for dematerialisation were mutilated and cancelled after verification.
• Depository name substituted as registered owner within prescribed timelines.

Financial Performance and Key Metrics

• FY25 revenue ₹880 crore with 21% growth in Revenue from Operations.
• Operating profit increased by 13%, PAT grew by 33% in FY25.
• Profit from Operations margin at 37%, ROCE at 62.5%.
• Domestic sales grew 22% in Q4; excluding recall impact growth was 11%.

Business Strategy and Growth Drivers

• Focus on profitable growth through brand equity investment and self-choice market.
• Key brands: Avil (#1 volume), Allegra (#3 value), Combiflam (#5), DePURA (top 5 Vitamin D).
• Strategy pillars: scale HCP reach, scale consumer engagement, improve direct retail access.
• Plan to double face-to-face HCP reach in 2026; digital HCP engagement also expanding.
• Increased A&P spends started Q2 FY25, continuing to build brand presence.
• Digital and AI investments enable faster creative production and data-driven decisions.
• Supply chain fully independent, nearly 100% production in India for stock control.
• Categories have large growth headroom: allergy (30% affected), pain (90% episodes), Vitamin D deficiency (70%).
• Consumer self-medication rising; 53 million online health queries, 25% self-medicate, 15% consult pharmacists.
• Innovation pipeline active; Allegra D launched last year; more launches planned.
• Evaluating expansion into new categories beyond pain, allergy, nutrients.
• Field force of ~350 medical reps, digitally enabled with AI-supported content.
• Regional strength in North India; East region targeted for growth; West and South aligned with category.

Corporate Social Responsibility and Culture

• Project Amrit provided clean drinking water to 200,000 people in last year.
• Van Mitra project planted 34,000 trees, reducing 400 tons of CO₂ emissions.
• Certified as a B-Corp for ethics, social and environmental performance.
• Diversity improved with women employees doubling in one year; recognized as preferred workplace.
• Culture focus on challenger mindset, KPI-driven performance, and rewarding excellence.

Q&A Highlights

• Analysts asked about India focus; management confirmed growth and profitable growth priority.
• Pipeline products under evaluation; Allegra D cited as recent innovation; other products remain with same team.
• OTC policy pending; expected to enable direct consumer communication and category building.
• E-commerce and modern trade contribute single-digit sales; growing faster than core business.
• Plan to double HCP coverage face-to-face in 2026.
• Considering both internal sales force productivity and third-party MR models for reach expansion.
• Field force digitally enabled with AI content; 350 medical reps currently.
• Regional reach strong in North; East targeted for expansion; West and South aligned with category.
• Post-recall, two of four brands regained pre-recall run rates; HCP feedback positive on brand superiority.
• CMO network well diversified; no supply concerns.
• Investment in brand building started Q2 FY25; will continue to grow.
• Growth measured by top line, market share gain, and bottom line; must outperform market growth.
• Inorganic growth opportunities under discussion; global group open but evaluating options.
• Sustainable profitable growth prioritized; margin impact managed carefully with focused spending.
• Considering brand extensions that allow direct consumer communication, e.g., Combiflam cream.
• No forward-looking financial guidance provided.